US Cancer Mortality Drops

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

Cancer remains the second leading cause of death in the United States, but the disease's mortality rate declined by 2.9% in 2004, according to the Centers for Disease Control and Prevention (CDC). Total US cancer deaths in 2004 numbered 550,270. Preliminary mortality data put the age-adjusted death rate for malignant neoplasms at 184.6 per 100,000 population, down from 190.1 in 2003. The nation's overall death rate fell to a record low of 801 per 100,000 persons, down from 833 the previous year. The preliminary data are based on approximately 90% of the 2004 death records reported by the 50 states.

WASHINGTON—Cancer remains the second leading cause of death in the United States, but the disease's mortality rate declined by 2.9% in 2004, according to the Centers for Disease Control and Prevention (CDC). Total US cancer deaths in 2004 numbered 550,270. Preliminary mortality data put the age-adjusted death rate for malignant neoplasms at 184.6 per 100,000 population, down from 190.1 in 2003. The nation's overall death rate fell to a record low of 801 per 100,000 persons, down from 833 the previous year. The preliminary data are based on approximately 90% of the 2004 death records reported by the 50 states.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content